Efficacy Study of Yi-Zhi-An-Shen Granules For Older Adults With Amnestic Mild Cognitive Impairment: a Randomized, Double-blind, Placebo-controlled Study
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Change from Baseline in Alzheimer´s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score
研究概览
简要总结
The main purpose of this study is to investigate the safety and efficacy of Yi-Zhi-An-Shen Granules in participants with amnestic mild cognitive impairment (aMCI).
详细描述
The investigators performed a randomized, placebo-controlled, double-blind study on evaluating effect of Yi-Zhi-An-Shen Granules on cognition, sleep quality, and gut microbiome of older adults with amnestic mild cognitive impairment (aMCI). The investigators plan to involve 80 cases for observation in 2 years (40 cases for each group), expecting that cognition and sleep quality of aMCI patients can be improved by Yi-Zhi-An-Shen Granules versus placebo, and discussing the differences between individuals with aMCI and ones with normal cognition, also investigating whether this Chinese medicine compound can regulate gut microbiome of older individuals with aMCI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 60 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject has assigned informed consent to participate in the study and continues to give willing consent for participation
- •Age from 60 to 85 years with a diagnosis of aMCI
- •Educational level of at least 6 years
- •Availability of a "study partner" who can assist in completing rating scales for the duration of the study
- •Cognitive complaints reported by the subject and confirmed by the "study partner"
- •Clinical Dementia Rating (CDR) global score of 0.5, and memory item score of 0.5
- •Mini-mental state examination (MMSE) score of 24-30
- •Diagnostic and Statistical Manual of Mental Disorders, Version 5 (DSM-V) criteria of dementia not fulfilled
排除标准
- •Has been previously enrolled in this study and received the investigational product
- •Has received an investigational product within 30 days prior to screening
- •Has received disease-modifying therapy
- •Has a known allergy to the study drug or any of its constituents
- •Has a history of alcohol abuse or alcohol dependency in the 3 years prior to study entry, or is an alcoholic or drug addict, as determined by the investigator
- •Has ongoing clinically significant (as judged by the investigator), metabolic or any other disease that could currently cause impaired memory (e.g., untreated thyroid disease, vitamin or other nutritional deficiencies, chronic kidney, or liver disease)
- •Memory impairment that can be attributed to a disease or condition other than an early phase neurodegenerative syndrome
- •Has a parkinsonian movement disorder
- •Use of psychoactive medications that would affect the subject's ability to reliably perform neurocognitive testing or create uncertainty in distinguishing between the effects of the psychoactive medication and the subject's underlying cognitive impairment (e.g., benzodiazepines, sedatives, antipsychotics)
- •History of major recurrent depressive disorder (DSM-V) within the last 5 years prior to screening
- •Has a brain tumor or other intracranial lesion, a disturbance of cerebral spinal fluid circulation (e.g., normal pressure hydrocephalus), and/or a significant history of head trauma or brain surgery
- •Has signs of major cerebrovascular disease, with score of modified Hachinski Ischemia Score (mHIS) at more than 4, or as verified by medical history and/or brain MRI or CT
- •Has severe visual or hearing impairments that cannot cooperate with examinations
- •Has severe digestive system diseases
- •Has received antibiotics within 60 days prior to screening
研究组 & 干预措施
Yi-Zhi-An-Shen
Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
干预措施: Yi-Zhi-An-Shen (Drug)
Placebo
Placebo given three times every day for 16 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in Alzheimer´s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score
时间窗: Baseline, 16 weeks, 22 months
The ADAS-Cog was developed as an outcome measure for global cognition in clinical trials. The ADAS-Cog assesses multiple cognitive domains including memory, language, praxis, and orientation, for a total of 70 points (0: no cognitive impairment; 70: severe impairment). An improvement of 4 points is used as a criterion of clinically effective anti-dementia drugs.
次要结局
- Change from Baseline in the Montreal Cognitive Assessment (MoCA)(Baseline, 8 weeks, 16 weeks, 10 months, 16 months, 22 months)
- Change from Baseline in the Clinical Dementia Rating Scale (CDR)(Baseline, 16 weeks, 22 months)
- Change from Baseline in the Activity of Daily Living (ADL)(Baseline, 8 weeks, 16 weeks, 10 months, 16 months, 22 months)
- Change from Baseline in the Mini Mental Status Examination (MMSE)(Baseline, 8 weeks, 16 weeks, 10 months, 16 months, 22 months)
- Change from Baseline in the Pittsburgh sleep quality index (PSQI)(Baseline, 8 weeks, 16 weeks, 10 months, 16 months, 22 months)
- Differences between patients with aMCI and individuals with normal cognition in gut microbiome.(Baseline, 16 Weeks)